In evidence

We’re very glad to announce the 4th Workshop Purification Therapies ‘From Research to Clinics: The End of the Beginning'

At the end of the year, Purification Therapies Journey 2021 came to an end.

CytoSorbents (USA) and Aferetica announce the European Union's approval for clinical use of the integrated PerLife® system and the "PerSorb ECOS-300CY ™" sorbent

Second update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe COVID-19 infection

We consider important to share an update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe infection with COVID-19

In the recent days, we have witnessed the multiplication of cases of Covid-19 infection in Italy and Worldwide. Although this event should not be dramatized, we know that a percentage of these patients might present possible complications, leading to the admission in ICU, during which extracorporeal circulation support therapies might be often necessary. Adjuvant therapies such as sorbent therapy with CytoSorb can be applied alongside these treatments. The situation evolves day by day and, both Aferetica in Italy and CytoSorbents in the rest of the World, have received pressing requests for the indications on the possible use of CytoSorb for [...]

We are proud to announce that from today the fight against the Sepsis, the world's leading cause of hospital death, has a new ally.

CytoSorb® Registry is an independent international registry coordinated by the University Hospital of Jena and aimed at collecting data of all patients treated with CytoSorb®.